Women on CagriSema lost an estimated 25% of body weight in a REDEFINE 1 analysis
The post hoc look at 2,300+ women, shown at The Menopause Society meeting, splits results by menopause stage. FDA decision expected late 2026.
Recap by typeshit. Full story at NewBeauty.